Dendritic cells vaccine(Universidad de Navarra)

In this phase II study, patients with solid tumors will receive treatment with hiltonol and autologous dendritic cells.

Primary outcome measure:
a.Evaluation of the treatment impact on progression-free survival.
Secondary outcome measures:
Safety evaluation.
Direct effects attributable cell obtaining and administration.
Adverse events during treatment.
Neurological deterioration quantified using the NIH Stroke Scale.
Autoimmune phenomena.
Evaluation of impact on other efficiency clinical parameters.
Overall survival.
Quality of life measured with EORTC questionnaire.
Study of specific immune response and correlates with clinical outcome.
Delayed hypersensitivity.
Humoral response to autologous tumor cells/tumoral lysate.
Cellular response (proliferation, cytokine production, specific cytotoxicity).
Cell line characterization and correlate the final product with clinical efficacy.
Phenotypic studies.